Pipeline

June 15, 2020

Company	Drug/Device	Medical Condition	Status
COVID-19 Trials and Actions
Tychan	TY027	COVID-19	initiation of phase 1 trial
Eli Lilly Junshi Biosciences	JS016 monotherapy and combined with other antibodies	COVID-19	first patient dosed in phase 1 trial
Immunic	IMU-838	patients with moderate COVID-19	IND approved by the FDA
ChromaCode	HDPCR SARS-CoV-2 Real-Time PCR Assay	detection of SARS-CoV-2	Emergency Use Authorization (EUA) granted by the FDA
Genetron Holdings	Genetron SARS-CoV-2 RNA Test	detection of SARS-CoV-2	EUA granted by the FDA
Illumina	Illumina COVIDSeq Test	detection of SARS-CoV-2	EUA granted by the FDA
Phosphorus Diagnostics	at home saliva test for COVID-19	detection of COVID-19	EUA granted by the FDA
Premier Biotech	COVID-19 IgG and IgM rapid test	detection of COVID-19	EUA granted by the FDA
Quidel	Sofia SARS Antigen FIA	rapid point-of-care test for COVID-19	EUA granted by the FDA
Other Trials and Actions
Neurana Pharmaceutical	tolperisone skeletal muscle relaxant	acute, painful muscle spasms without drowsiness or impact on cognititve function	initiation of phase 1 study
Arcturus Therapeutics	ARCT-810	Ornithine Transcarbamylase (OTC) deficiency	first patient dosed in phase 1 trial
Revolution Medicines	RMC-4630 plus AMG510	advanced solid tumors harboring the KRASG12C mutation	first patient dosed in phase 1b trial
Precision BioSciences	PBCAR269A	relapsed/refractory multiple myeloma	first patient dosed in phase 1/2a trial
NanOlogy	IT NanoPac (submicron particle paclitaxel)	non-small cell lung cancer and small cell lung cancer	initiation of phase 2a trial
PDS Biotechnology	PDS0101, in combination with standard of care chemoradiotherapy	locally advanced cervical cancer	initiation of phase 2 trial
Devonian Health Group	Thykamine	mild-to-moderate atopic dermatitis	completion of patient enrollment in phase 2 trial
Sound Pharmaceutical	SPI-1005	Meniere's Disease	initiation of phase 3 trial
Clovis Oncology	Rubraca (rucaparib) plus Opdivo (nivolumab)	front-line maintenance treatment of newly diagnosed advanced ovarian cancer	completion of patient enrollment in phase 3 trial
Bacainn Therapeutics	BT051	ulcerative colitis	IND approved by the FDA
Baylx	BX-U001, human umbilical cord tissue mesenchymal stem cells	rheumatoid arthritis	IND approved by the FDA
Curis	CI-8993	relapsed or refractory solid tumors	IND approved by the FDA
Elixirgen Therapeutics	EXG4217	telomere biology disorders with bone marrow failure	IND approved by the FDA
Sapience Therapeutics	ST101	adults with unresectable and metastatic solid tumors	IND approved by the FDA
AlgoTherapeutix	ATX01 (proprietary topical amitriptyline)	erythromelalgia	Orphan Drug designation granted by the FDA
MacroGenics	margetuximab	HER2-positive gastric cancer or gastroesophageal junction cancer	Orphan Drug designation granted by the FDA
Polyneuron Pharmaceutical	PN 1007 (PPSGG)	anti-MAG neuropathy	Orphan Drug designation granted by the FDA
TVAX Biomedical	vaccine-enhanced adoptive T-cell therapy (VACT)	glioblastoma multiforme	Fast Track designation granted by the FDA
Insmed	brensocatib (INS1007)	non-cystic fibrosis bronchiectasis	Breakthrough Therapy designation granted by the FDA
Rezolute	RZ358	congenital hyperinsulinism	Rare Pediatric Disease designation granted by the FDA
Bristol-Myers Squibb	Opdivo (nivolumab)	patients with unresectable advanced, recurrent or metastatic esophageal squamous cell carcinoma after prior fluoropyrimidine- and platinum-based chemotherapy	approved by the FDA
Merck	Recarbio	hospital-acquired and ventilator-associated pneumonia caused by gram negative bacteria	approved by the FDA for expanded indication